e-learning
resources
London 2016
Monday, 05.09.2016
Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients
Marcel Hoppentocht (Groningen, Netherlands), Marcel Hoppentocht, Onno Akkerman, Paul Hagedoorn, Jan-Willem Alffenaar, Tjip van der Werf, Huib Kerstjens, Henderik Frijlink, Anne de Boer
Source:
International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Session:
Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Session type:
Thematic Poster
Number:
2562
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Marcel Hoppentocht (Groningen, Netherlands), Marcel Hoppentocht, Onno Akkerman, Paul Hagedoorn, Jan-Willem Alffenaar, Tjip van der Werf, Huib Kerstjens, Henderik Frijlink, Anne de Boer. Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. Eur Respir J 2016; 48: Suppl. 60, 2562
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011
Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Inhaled steroids in children with non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 392s
Year: 2004
Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016
Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2007; 30: Suppl. 51, 528s
Year: 2007
Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Distribution of nebulised gentamicin in patients with bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 476-486
Year: 2013
Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Demographics and characteristics of antibiotic use in non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – From pleura to bronchi: new insights
Year: 2016
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Source: Eur Respir J 2002; 20: 122-126
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept